Events & Presentations
Date | Event Details | Remind Me |
---|---|---|
Sep 26, 2023 10:30 AM EDT
|
2023 Cantor Fitzgerald Global Healthcare Conference
|
Date | Event Details |
---|---|
Apr 8 - Apr 13, 2022
|
American Association for Cancer Research Annual Meeting 2022 (AACR)
AACR 2022 ARO-HIF2 Poster 1.6 MB
Title: Targeting HIF2a with siRNA: From preclinical models to the clinic
Authors: Yuanqing Ma, et al. |
Mar 30 - Apr 3, 2022
|
31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022)
APASL 2022 JNJ-3989 927.4 KB
Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Title: Short interfering RNA JNJ-3989 combination therapy in chronic |
Feb 17 - Feb 19, 2022
|
2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
San Francisco, CA and online
Presentation Details: Title: Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001) Authors: James Brugarolas, et al. Session: Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers Abstract Number: 339 Poster Number: F9 |
Feb 2, 2022 4:30 PM EST
|
Arrowhead Pharmaceuticals 2022 First Quarter Results
Prepared Remarks 206.2 KB
|
Dec 3, 2021
|
18th Global Cardiovascular Clinical Trialists Forum
View Presentation 1.1 MB
James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
|
Dec 2, 2021 1:00 PM EST
|
4th Annual Evercore ISI HealthCONx Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
Nov 30, 2021
|
Piper Sandler 33rd Annual Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
Nov 22, 2021 4:30 PM EST
|
Arrowhead Pharmaceuticals 2021 Year End Results
Prepared Remarks 210.1 KB
|
Nov 16, 2021 11:50 AM EST
|
Jefferies London Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
Nov 13 - Nov 17, 2021
|
American Heart Association (AHA) Scientific Sessions 2021
Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia |